We recently showed that patients with NAFLD have higher levels of IL-6, IL-8, IL-10, and CXCL10, and lower levels of IFN-γ, and these were associated with worse COVID-19 outcomes [16]. The gene discussed is CXCL10; the disease is metabolic dysfunction-associated steatotic liver disease.